1254351-84-2

Basic information

• Product Name: C₂₂H₁₉BrO₄
• Synonyms: C₂₂H₁₉BrO₄
• CAS NO: 1254351-84-2
• Molecular Weight: 427.294
• Mol File: 1254351-84-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₂₂H₁₉BrO₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₂H₁₉BrO₄(1254351-84-2)
• EPA Substance Registry System: C₂₂H₁₉BrO₄(1254351-84-2)

Safety Data

• Hazardous Substances Data: 1254351-84-2(Hazardous Substances Data)

Upstream product

• 108-95-2 phenol 
• 1175095-38-1 6-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 490-79-9 2,5-dihydroxybenzoic acid. 
• 35458-39-0 4-bromo-2,5-dimethoxybenzoic acid 
• 1260694-70-9 phenyl 3,6-dimethoxy-2-methylbenzoate 
• 116324-66-4 2,5-Dimethoxy-6-methylbenzoesaeure 
• 2785-98-0 2,5-dimethoxybenzoic acid 
• 2674-34-2 1,4-dibromo-2,5-dimethoxybenzene 
• 150-78-7 1,4-dimethoxybezene 
• 74-88-4 methyl iodide 
• 1254340-85-6 phenyl 4-bromo-2-methoxy-6-methylbenzoate 
• 1244949-43-6 4-bromo-2-methoxy-6-methyl-benzaldehyde 
• 1181458-21-8 (4-Bromo-2-methoxy-6-methyl-phenyl)-amine hydrobromide 
• 1254347-06-2 phenyl 4-bromo-2-hydroxy-6-methylbenzoate 

Downstream Products

• 1359022-10-8 C₂₈H₂₄O₄ 
• 1359021-86-5 C₃₁H₃₅NO₈ 
• 1359022-14-2 C₂₈H₂₈N₂O₈*ClH 
• 1359022-13-1 C₄₆H₅₄N₂O₁₀Si 
• 1359022-12-0 C₂₆H₂₆O₆ 
• 1359022-11-9 C₂₁H₁₈O₄ 
• 1359021-91-2 C₃₄H₃₇N₃O₉ 
• 1359021-90-1 C₄₅H₅₉N₃O₁₁Si 
• 1359021-89-8 C₂₅H₃₁NO₇ 
• 1359021-88-7 C₁₉H₂₁NO₅ 

Relevant articles and documents

Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability

Process research and development of the fully synthetic broad spectrum tetracycline TP-2758, with a chiral pyrrolidine side chain at the C-8 position, is described. The process utilizes two key intermediates, 7 and 10, in a convergent approach that allows for manufacturing of sufficient quantities of API to supply preclinical and early clinical development. The pyrrolidine moiety was introduced into the left-hand piece (LHP) 10 with high enantioselectivity using Ellman's sulfinamide chemistry, and the absolute configuration was confirmed by X-ray crystal structure analysis.

TETRACYCLINE ANALOGS

The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.